Lee, Holly
Ahn, Sungwoo
Maity, Ranjan
Leblay, Noemie http://orcid.org/0000-0002-4202-7127
Ziccheddu, Bachisio
Truger, Marietta
Chojnacka, Monika http://orcid.org/0000-0001-7176-6108
Cirrincione, Anthony
Durante, Michael http://orcid.org/0000-0003-3137-6847
Tilmont, Remi
Barakat, Elie
Poorebrahim, Mansour
Sinha, Sarthak http://orcid.org/0000-0002-0770-3150
McIntyre, John
M.Y. Chan, Angela
Wilson, Holly
Kyman, Shari http://orcid.org/0000-0001-5386-5866
Krishnan, Amrita
Landgren, Ola http://orcid.org/0000-0001-6485-4839
Walter, Wencke http://orcid.org/0000-0002-5083-9838
Meggendorfer, Manja http://orcid.org/0000-0002-9038-3265
Haferlach, Claudia
Haferlach, Torsten http://orcid.org/0000-0003-0196-2837
Einsele, Hermann http://orcid.org/0000-0002-7680-0819
Kortüm, Martin K. http://orcid.org/0000-0002-7011-0286
Knop, Stefan
Alberge, Jean Baptiste
Rosenwald, Andreas
Keats, Jonathan J. http://orcid.org/0000-0003-4375-7399
Rasche, Leo http://orcid.org/0000-0002-9536-9649
Maura, Francesco http://orcid.org/0000-0002-5017-1620
Neri, Paola
Bahlis, Nizar J. http://orcid.org/0000-0001-7353-7034
Article History
Received: 5 March 2023
Accepted: 5 July 2023
First Online: 31 August 2023
Competing interests
: N.J.B. has received research funding from Pfizer and speaker’s bureau honoraria from Amgen, BMS, Sanofi, Pfizer and Janssen; he is a consultant/advisory board member for BMS, Janssen and Pfizer. P.N. received speaker’s bureau honoraria from BMS, Janssen and Sanofi, and is a consultant/advisory board member for BMS and Janssen. C.H. and T.H. have equity ownership of MLL Munich Leukemia Laboratory. O.L. has received research funding from: the National Institutes of Health (NIH), NCI, US Food and Drug Administration, MMRF, International Myeloma Foundation, Leukemia and Lymphoma Society, the Paula and Rodger Riney Myeloma Foundation, Perelman Family Foundation, Rising Tide Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics and Karyopharm; received honoraria and is on advisory boards for Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno and Pfizer; and serves on independent data monitoring committees for clinical trials led by Takeda, Merck, Janssen and Theradex. J.J.K has received research funding from Amgen, Genentech and Janssen, and has received honoraria and is on advisory boards for Janssen. The other authors declare no competing interests.